Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 166

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 166
---
. Raza Bokhari     |           - | -           |      100,856 | -       | -            |            100,856 |
| Dr. Larry Kaiser     |      60,000 | -           |       30,257 | -       | -            |             90,257 |
| Robert J. Ciaruffoli |      75,000 | -           |       30,257 | -       | -            |            105,257 |
| Frank Lavelle        |      60,000 | -           |       30,257 | -       | -            |             90,257 |
| William L. Ashton    |      50,000 | -           |       30,257 | -       | -            |             80,257 |
| Barry Fishman        |      60,000 | -           |       30,257 | -       | -            |             90,257 |
| Dr. Sara R. May(2)   |      30,000 | -           |       76,051 | -       | -            |            106,051 |

(1)Other than Dr. Raza Bokhari, who did not receive any extra compensation for serving as Executive Chairman, all directors were paid $50,000 annually, in quarterly installments, as compensation for Board membership in 2024. In addition, committee Chairs received an annual compensation of $10,000, other than the Chair of the Audit Committee, who received $15,000, and Mr. Ciaruffoli, as the lead director, who received an additional $10,000 per annum.

(2)Dr. Sara R. May joined the Board in June 2024.

Directors' Service Contracts

There are no arrangements or understandings between us, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their service as directors of our company.

Employees

As of the date of this prospectus, we have 18 employees, all of which are full-time employees, except for two. None of our current employees were employees of Velocity Fund Partners or of SkinJect prior to the Business Combination.

<div align='center'>121</div>

Equity Incentive Plan

Background

The Board has adopted an Equity Incentive Plan (the "Plan"), which was approved by shareholders on July 28, 2023. The Plan